prikaz prve stranice dokumenta The role of the NY-ESO-1 in the prognosis of gastric cancer
  Preuzmi
PDF 1.6 MB
Znanstveni rad - Izvorni znanstveni rad
The role of the NY-ESO-1 in the prognosis of gastric cancer
Biomolecules and Biomedicine, 24 (2024), 4; 813-820. https://doi.org/10.17305/bb.2023.9937
Misir, Zvonimir; Glavčić, Goran; Janković, Suzana; Kruljac, Ivan; Čugura-Filipović, Jakša; Čimić, Kristina; Ulamec, Monika

Citiranost:
,
Citirajte ovaj rad

Misir, Z., Glavčić, G., Janković, S., Kruljac, I., Čugura Filipović, J., Čimić, K. i Ulamec, M. (2024). The role of the NY-ESO-1 in the prognosis of gastric cancer. Biomolecules and Biomedicine, 24. (4), 813-820. doi: 10.17305/bb.2023.9937

Misir, Zvonimir, et al. "The role of the NY-ESO-1 in the prognosis of gastric cancer." Biomolecules and Biomedicine, vol. 24, br. 4, 2024, str. 813-820. https://doi.org/10.17305/bb.2023.9937

Misir, Zvonimir, Goran Glavčić, Suzana Janković, Ivan Kruljac, Jakša Čugura Filipović, Kristina Čimić i Monika Ulamec. "The role of the NY-ESO-1 in the prognosis of gastric cancer." Biomolecules and Biomedicine 24, br. 4 (2024): 813-820. https://doi.org/10.17305/bb.2023.9937

Misir, Z., et al. (2024) 'The role of the NY-ESO-1 in the prognosis of gastric cancer', Biomolecules and Biomedicine, 24(4), str. 813-820. doi: 10.17305/bb.2023.9937

Misir Z, Glavčić G, Janković S, Kruljac I, Čugura Filipović J, Čimić K, i sur.. The role of the NY-ESO-1 in the prognosis of gastric cancer. Biomolecules and Biomedicine [Internet]. 2024. [pristupljeno 05.04.2025.];24(4):813-820. doi: 10.17305/bb.2023.9937

Z. Misir, et al., "The role of the NY-ESO-1 in the prognosis of gastric cancer", Biomolecules and Biomedicine, vol. 24, br. 4, str. 813-820, 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:421558. [Citirano: 05.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:421558
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The role of the NY-ESO-1 in the prognosis of gastric cancer
AutorZvonimir Misir
AutorGoran Glavčić
AutorSuzana Janković
AutorIvan Kruljac
AutorJakša Čugura-Filipović
AutorKristina Čimić
AutorMonika Ulamec
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Kirurgija
Sažetak (engleski)
Gastric cancer (GC) is one of the most common malignancies worldwide and the fourth leading cause of cancer-related deaths. GC is a multifactorial disease influenced by both environmental and genetic factors. Its most critical features include invasiveness and high metastatic potential. Metastasis is a complex process, and our understanding of the mechanisms involved remains incomplete. Growing evidence suggests that cancer-testis antigens (CTAs) play a crucial role in the metastatic potential... Više of various tumors. Several studies have linked CTA expression with lower tumor differentiation, higher metastatic potential, and poor chemotherapy response. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) antigen, part of the CTA group, is expressed in tumor tissues, while its expression in normal tissues is restricted to spermatogonia. This study aimed to determine the expression of NY-ESO-1 in primary adenocarcinoma of the stomach, both with and without metastasis in regional lymph nodes, and to compare it with TNM stage, age, gender, and survival. We analyzed GC tissue from 53 node-negative and 55 node-positive primary gastric carcinoma patients for NY-ESO-1 expression using immunohistochemical assay. The results were correlated with clinicopathological parameters and survival. Patients with positive NY-ESO-1 expression in primary tumors had a median survival of 19.0 months (range 14.1–24.0), in contrast to those with negative expression, who had a median survival of 52.0 months (range 0.0–133.3) (chi-square 7.99, P = 0.005). T status, N status, and NY-ESO-1 expression were all independently associated with shorter survival. No significant difference in NY-ESO-1 expression in primary tumors was observed concerning lymph node metastasis status. In summary, our findings suggest that increased expression of NY-ESO-1 could potentially serve as a prognostic biomarker for GC. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomolecules and Biomedicine
Brojčani podacivol. 24, br. 4, str. 813-820
p-ISSN2831-0896
e-ISSN2831-090X
DOIhttps://doi.org/10.17305/bb.2023.9937
URN:NBNurn:nbn:hr:220:421558
Datum objave publikacije2024
URL dokumentahttps://www.bjbms.org/ojs/index.php/bjbms/article/view/9937
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2025-03-14 13:30:55
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.